| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $4,030,050 | 10 | 100 |
Sells | $0 | 0 | 0 |
| Shenouda Maged | Chief Financial Officer | 4 | $1.99M | 0 | $0 | $1.99M |
| TRAVERSA SERGIO | Chief Executive Officer | 4 | $1.54M | 0 | $0 | $1.54M |
| Ence Chuck | CAO and COO | 1 | $299,200 | 0 | $0 | $299,200 |
| Kelly Paul Edward | Chief Operating Officer | 1 | $198,000 | 0 | $0 | $198,000 |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive …
Over the last 12 months, insiders at Relmada Therapeutics, Inc. have bought $4.03M and sold $0 worth of Relmada Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Relmada Therapeutics, Inc. have bought $1.53M and sold $470,621 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Shenouda Maged (Chief Financial Officer) — $1.99M. TRAVERSA SERGIO (Chief Executive Officer) — $1.54M. Ence Chuck (CAO and COO) — $299,200.
The last purchase of 100,000 shares for transaction amount of $410,000 was made by TRAVERSA SERGIO (Chief Executive Officer) on 2026‑09‑10.
| 2026-09-10 | TRAVERSA SERGIO | Chief Executive Officer | 100,000 0.096% | $4.10 | $410,000 | -12.90% | ||
| 2026-09-10 | Shenouda Maged | Chief Financial Officer | 79,800 0.0794% | $4.25 | $339,150 | -12.90% | ||
| 2026-09-09 | TRAVERSA SERGIO | Chief Executive Officer | 100,000 0.0974% | $4.18 | $418,000 | -12.47% | ||
| 2026-09-09 | Shenouda Maged | Chief Financial Officer | 120,200 0.1177% | $4.20 | $504,840 | -12.47% | ||
| 2025-12-15 | TRAVERSA SERGIO | Chief Executive Officer | 27,500 0.0355% | $4.12 | $113,300 | +9.75% | ||
| 2025-12-15 | Shenouda Maged | Chief Financial Officer | 11,665 0.015% | $4.12 | $48,060 | +9.75% | ||
| 2025-11-05 | TRAVERSA SERGIO | Chief Executive Officer | 272,500 0.7992% | $2.20 | $599,500 | +81.27% | ||
| 2025-11-05 | Shenouda Maged | Chief Financial Officer | 500,000 1.4664% | $2.20 | $1.1M | +81.27% | ||
| 2025-11-05 | Kelly Paul Edward | Chief Operating Officer | 90,000 0.264% | $2.20 | $198,000 | +81.27% | ||
| 2025-11-05 | Ence Chuck | CAO and COO | 136,000 0.3989% | $2.20 | $299,200 | +81.27% | ||
| 2025-08-28 | TRAVERSA SERGIO | Chief Executive Officer | 55,976 0.161% | $0.74 | $41,422 | +485.81% | ||
| 2025-08-27 | TRAVERSA SERGIO | Chief Executive Officer | 129,455 0.3903% | $0.67 | $86,735 | +578.12% | ||
| 2025-08-26 | TRAVERSA SERGIO | Chief Executive Officer | 80,545 0.24% | $0.62 | $49,938 | +586.42% | ||
| 2025-05-20 | TRAVERSA SERGIO | Chief Executive Officer | 147,686 0.4151% | $0.56 | $82,246 | +523.12% | ||
| 2025-05-20 | Shenouda Maged | Chief Financial Officer | 60,000 0.1586% | $0.52 | $31,422 | +523.12% | ||
| 2025-05-19 | TRAVERSA SERGIO | Chief Executive Officer | 30,000 0.0888% | $0.50 | $14,994 | +617.09% | ||
| 2025-05-19 | Shenouda Maged | Chief Financial Officer | 90,000 0.2586% | $0.49 | $43,686 | +617.09% | ||
| 2025-05-16 | TRAVERSA SERGIO | Chief Executive Officer | 172,314 0.5063% | $0.45 | $77,472 | +685.25% | ||
| 2025-05-16 | Kelly Paul Edward | Chief Operating Officer | 200,000 0.5624% | $0.43 | $86,060 | +685.25% | ||
| 2025-05-16 | Ence Chuck | CA and CO | 228,961 0.6753% | $0.45 | $103,330 | +685.25% |
| TRAVERSA SERGIO | Chief Executive Officer | 1500000 1.4062% | $6.41M | 19 | 14 | +263.45% |
| Shenouda Maged | Chief Financial Officer | 1000000 0.9375% | $4.27M | 16 | 14 | +176.69% |
| Kelly Paul Edward | Chief Operating Officer | 502295 0.4709% | $2.14M | 8 | 11 | +208.18% |
| Ence Chuck | CAO and COO | 403931 0.3787% | $1.72M | 5 | 0 | +160.99% |
| SETH SANDESH | director | 123258 0.1156% | $526,311.66 | 2 | 0 | |
| CASAMENTO CHARLES J | director | 13000 0.0122% | $55,510.00 | 2 | 15 | <0.0001% |
| O'Gorman Cedric | Chief Medical Officer | 10121 0.0095% | $43,216.67 | 1 | 0 | +0.32% |
| Agharkar Shreeram | director | 5759 0.0054% | $24,590.93 | 2 | 0 |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
Relmada Therapeutics, Inc. (RLMD) | $2,481,409 | 33 | 201.68% | $455.48M |
| Increased Positions | 57 | +183.87% | 43M | +560.67% |
| Decreased Positions | 9 | -29.03% | 217,832 | -2.81% |
| New Positions | 35 | New | 34M | New |
| Sold Out Positions | <1 | Sold Out | 1,581 | Sold Out |
| Total Postitions | 79 | +154.84% | 51M | +557.86% |
| Ikarian Capital, Llc | $8,054.00 | 2.53% | 1.84M | +2M | +4,476.76% | 2025-09-30 |
| Driehaus Capital Management Llc | $3,234.00 | 1.01% | 740,006 | 0 | 0% | 2025-09-30 |
| Boothbay Fund Management, Llc | $3,029.00 | 0.95% | 693,236 | +693,236 | New | 2025-09-30 |
| Acadian Asset Management Llc | $2,546.00 | 0.8% | 582,543 | -36,936 | -5.96% | 2025-09-30 |
| Blackrock, Inc. | $2,220.00 | 0.7% | 508,000 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $1,829.00 | 0.57% | 418,580 | +54,503 | +14.97% | 2025-09-30 |
| Advisorshares Investments Llc | $1,763.00 | 0.55% | 403,488 | +6,974 | +1.76% | 2025-09-30 |
| Geode Capital Management, Llc | $1,294.00 | 0.41% | 296,215 | -6,139 | -2.03% | 2025-09-30 |
| Marshall Wace, Llp | $1,189.00 | 0.37% | 272,053 | +117,485 | +76.01% | 2025-09-30 |
| Deutsche Bank Ag | $983.00 | 0.31% | 224,846 | 0 | 0% | 2025-09-30 |